609 A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Advanced Solid Tumors
Haluska P, Menefee M, Plimack E, Rosenberg J, Northfelt D, LaVallee T, Huang W, Yu X, Viner J, LoRusso P. 609 A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Advanced Solid Tumors. European Journal Of Cancer 2012, 48: 187-188. DOI: 10.1016/s0959-8049(12)72406-1.Peer-Reviewed Original ResearchInvestigational monoclonal antibodyAdvanced solid tumorsPhase 1 studyMEDI-573IGF-IISolid tumorsMonoclonal antibodiesAntitumor activityIGFPharmacokineticsTumorsAntibodiesSafety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors.
Haluska P, Menefee M, Plimack E, Rosenberg J, Northfelt D, LaVallee T, Huang W, Yu X, Viner J, LoRusso P. Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2012, 30: tps2618-tps2618. DOI: 10.1200/jco.2012.30.15_suppl.tps2618.Peer-Reviewed Original ResearchMEDI-573Advanced solid tumorsSolid tumorsAdult patientsGlucose homeostasisDose levelsDrug-related adverse eventsMedian age 64 yearsAdequate organ functionIGF-I/-IIInvestigational monoclonal antibodyAntitumor activityAcceptable safety profileAdvanced bladder cancerAge 64 yearsKarnofsky statusQ3W dosingStable diseaseAdverse eventsSafety profileIGF-IIBladder cancerSerum glucoseSerious toxicityIGF-1R